AI Analysis Reveals Efficacy In Severe Stroke Patients
Filed with ASX · · 9 pages · English
• ARG-007 delivered statistically significant improvement in follow up infarct volume and functional outcomes in more severe stroke patients when stroke severity scoring was standardised using an FDA approved AI tool. • Functional outcomes measured by the NIH Stroke Scale (NIHSS) at 24hours and the modified Rankin Scale at 90 days were significantly improved compared to placebo (p=0.011 and p=0.00
Argenica Therapeutics Ltd on 6ix
Earlier from Argenica Therapeutics
- Positive TNK Study Results Fulfil Key FDA Requirement
- ARG-007 Efficacious Dose Validated in New Preclinical Study
- Phase 2 Trial Promising Improvements in Functional Outcomes
- Topline Phase 2 Trial Results of ARG-007 in AIS Patients
- Trading Halt
Later from Argenica Therapeutics
- Quarterly Activities/Appendix 4C Cash Flow Report
- Successful Applicaton for EMA Paediatric Waiver
- Half Yearly Report and Accounts
- Argenica Receives $3.97m R&D Tax Incentive Cash Rebate
- Presentations at European Stroke Organisation Conference
Follow Argenica Therapeutics into a list and get an email when it puts out news.
Follow Argenica Therapeutics